Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 59, Issue -, Pages 43-51Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2021.04.009
Keywords
-
Categories
Ask authors/readers for more resources
Targeted protein degradation, particularly through bifunctional small-molecule degraders, shows promise in oncology therapy and has advanced clinically. Guidelines, reagents, and technologies have evolved to support research and development in this field.
The field of targeted protein degradation encompasses a growing number of modalities that achieve potent and selective knockdown of target proteins at the post-translational level. Among the most clinically advanced are bifunctional small-molecule degraders, also referred to as PROteolysis Targeting Chimeras, Degronimids, SNIPERs, or uSMITEs. Although applicable to many disease indications, oncology stands to be the first to benefit from this promising therapeutic approach, with the first investigational new drugs (INDs) filed in 2019 and a proliferation of research specifically focused on harnessing degraders for cancer treatment. In this review, we consider the toolbox of guidelines, reagents, and technologies that has evolved alongside the field to support degrader research and development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available